作者
Anne H Tavenier, Roxana Mehran, Mauro Chiarito, Davide Cao, Carlo A Pivato, Johny Nicolas, Frans Beerkens, Matteo Nardin, Samantha Sartori, Usman Baber, Dominick J Angiolillo, Davide Capodanno, Marco Valgimigli, Renicus S Hermanides, Arnoud WJ van ‘t Hof, Jur M Ten Berg, Kiyuk Chang, Annapoorna S Kini, Samin K Sharma, George Dangas
发表日期
2022/9
期刊
European Heart Journal-Cardiovascular Pharmacotherapy
卷号
8
期号
5
页码范围
492-502
出版商
Oxford University Press
简介
Aim
Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and bleeding risks. Various DAPT de-escalation strategies, defined as switching from a full-dose potent to a reduced dose or less potent P2Y12 inhibitor, have been evaluated in several ACS-PCI trials. We aimed to compare DAPT de-escalation to standard DAPT with full-dose potent P2Y12 inhibitors in ACS patients who underwent PCI.
Methods and results
PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials were searched for eligible randomized controlled trials. Aspirin monotherapy trials were excluded. Five randomized trials (n = 10 779 patients) that assigned DAPT de-escalation (genetically guided to clopidogrel n = 1242; platelet function guided to clopidogrel n = 1304 …
学术搜索中的文章
AH Tavenier, R Mehran, M Chiarito, D Cao, CA Pivato… - European Heart Journal-Cardiovascular …, 2022